USFDA nod to Caplin Steriles Timolol Maleate Ophthalmic Solution
Chennai: Caplin Steriles Limited, a Subsidiary Company of Caplin Point Laboratories Limited, has been granted final approval by the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Timolol Maleate Ophthalmic Solution USP, 0.5% (Eye drops).
It is a generic therapeutic equivalent version of the Reference Listed Drug (RLD) TIMOPTIC, from Bausch and Lomb Inc.
Timolol Maleate Ophthalmic Solution USP, 0.5% (Eye drops) is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma.
According to IQVIA (IMS Health), Timolol Maleate Ophthalmic Solution USP, 0.5% had US sales of approximately $45 million for the 12-month period ending June 2024.
Medical Dialogues team had earlier reported that the Company had received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Phenylephrine hydrochloride Ophthalmic Solution USP 2.5% and 10% (eye drops).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.